Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer

Fulvestrant 500 mg is standard of care for endocrine therapy‐naive or pretreated women with hormone receptor‐positive (HR+) metastatic breast cancer (MBC). This study was conducted to explore the potential factors and duration of last endocrine therapy as predictors for the efficacy of fulvestrant 5...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Med
Prif Awduron: Zhao, Yannan, Li, Yi, Gong, Chengcheng, Xie, Yizhao, Zhang, Jian, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Wang, Biyun, Hu, Xichun
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Clinical Cancer Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724295/
https://ncbi.nlm.nih.gov/pubmed/33022852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3491
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg